Common Contracts
5 similar null contracts by Amgen Inc
AMGEN INC. $1,000,000,000 3.200% SENIOR NOTES DUE 2027 Underwriting AgreementAmgen Inc • November 2nd, 2017 • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $1,000,000,000 principal amount of its 3.200% Senior Notes due 2027 (the “Securities”) to be issued pursuant to the provisions of an Indenture dated as of May 22, 2014 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as Trustee (the “Trustee”). J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BNP Paribas Securities Corp. have agreed to act as representatives of the Underwriters (the “Representatives”).
AMGEN INC. $850,000,000 1.250% SENIOR NOTES DUE 2017 $1,400,000,000 2.200% SENIOR NOTES DUE 2019 $1,400,000,000 3.625% SENIOR NOTES DUE 2024 $600,000,000 SENIOR FLOATING RATE NOTES DUE 2017 $250,000,000 SENIOR FLOATING RATE NOTES DUE 2019 Underwriting...Amgen Inc • May 22nd, 2014 • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $850,000,000 principal amount of the 1.250% Senior Notes due 2017 of the Company (the “2017 Notes”), an aggregate of $1,400,000,000 principal amount of the 2.200% Senior Notes due 2019 of the Company (the “2019 Notes”), an aggregate of $1,400,000,000 principal amount of the 3.625% Senior Notes due 2024 of the Company (the “2024 Notes”), an aggregate of $600,000,000 principal amount of the Senior Floating Rate Notes due 2017 of the Company (the “2017 Floating Notes”) and an aggregate of $250,000,000 principal amount of the Senior Floating Rate Notes due 2019 of the Company (the “2019 Floating Notes”, and together with the 2017 Notes, the 2019 Notes, the 2024 Notes and the 2017 Floating Notes, collectively, the “Securities”) to be issued pursuant to the provisions of an Indent
AMGEN INC. $1,250,000,000 2.125% SENIOR NOTES DUE 2017 $750,000,000 3.625% SENIOR NOTES DUE 2022 $1,000,000,000 5.375% SENIOR NOTES DUE 2043 Underwriting AgreementAmgen Inc • May 15th, 2012 • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $1,250,000,000 principal amount of the 2.125% Senior Notes due 2017 of the Company (the “2017 Notes”), an aggregate of $750,000,000 principal amount of the 3.625% Senior Notes due 2022 of the Company (the “2022 Notes”) and an aggregate of $1,000,000,000 principal amount of the 5.375% Senior Notes due 2043 of the Company (the “2043 Notes”, and together with the 2017 Notes and the 2022 Notes, collectively,
AMGEN INC. $1,000,000,000 1.875% SENIOR NOTES DUE 2014 $1,000,000,000 2.50% SENIOR NOTES DUE 2016 $1,750,000,000 3.875% SENIOR NOTES DUE 2021 $2,250,000,000 5.15% SENIOR NOTES DUE 2041 Underwriting AgreementAmgen Inc • November 10th, 2011 • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $1,000,000,000 principal amount of the 1.875% Senior Notes due 2014 of the Company (the “2014 Notes”), an aggregate of $1,000,000,000 principal amount of the 2.50% Senior Notes due 2016 of the Company (the “2016 Notes”), an aggregate of $1,750,000,000 principal amount of the 3.875% Senior Notes due 2021 of the Company (the “2021 Notes”) and an aggregate of $2,250,000,000 principal amount of the 5.15% Senior Notes due 2041 of the Company (the “2041 Notes”, and together with the 2014 Notes, the 2016 Notes and the 2021 Notes, collectively, the “Securities”) to be issued pursuant to the provisions of an Indenture, dated as of August 4, 2003 (the “Indenture”), between the Company and the Bank of New York Mellon, as successor to JPMorgan Chase Bank, N.A., as Trustee (the “Trustee”
AMGEN INC. $750,000,000 2.30% SENIOR NOTES DUE 2016 $1,000,000,000 4.10% SENIOR NOTES DUE 2021 $1,250,000,000 5.65% SENIOR NOTES DUE 2042 Underwriting AgreementAmgen Inc • June 30th, 2011 • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $750,000,000 principal amount of the 2.30% Senior Notes due 2016 of the Company (the “2016 Notes”), an aggregate of $1,000,000,000 principal amount of the 4.10% Senior Notes due 2021 of the Company (the “2021 Notes”) and an aggregate of $1,250,000,000 principal amount of the 5.65% Senior Notes due 2042 of the Company (the “2042 Notes”, together with the 2016 Notes and the 2021 Notes, collectively, the “Securities”) to be issued pursuant to the provisions of an Indenture, dated as of August 4, 2003 (the “Indenture”), between the Company and the Bank of New York Mellon, as successor to JPMorgan Chase Bank, N.A., as Trustee (the “Trustee”).
